Xiaoling Wang

Xiaoling Wang is a distinguished academic and researcher currently serving as a Professor and Principal Investigator at Guangzhou Medical University since June 2018. With extensive experience as a Senior Scientist at 广州市香雪制药股份有限公司, Xiaoling specializes in developing novel affinity enhanced TCR-T cell therapy and GMP level lentivirus manufacturing. Prior roles include a Scientist at Intrexon Corporation, focusing on genome editing in primary and stem cells, a Research Fellow at City of Hope working on genome editing in human embryonic stem cells, and a Postdoctoral Fellow at UCSF where significant contributions were made in iPS reprogramming. Xiaoling holds a PhD in Pharmacology from the University at Buffalo, alongside degrees in Molecular Virology and Virology from Wuhan University, and a Certificate in Bioscience Management from Keck Graduate Institute.